Johns Hopkins Pathology Homepage Dictionary For Patients For Physicians Giving
GALLBLADDER AND BILE DUCT CANCER
Understanding Gallbladder and Bile Duct Cancer Gallbladder and Bile Duct Cancer at Johns Hopkins What's New with Gallbladder and Bile Duct Cancer? Personal Stories Coping with Gallbladder and Bile Duct Cancer Resources for Gallbladder and Bile Duct Cancer


  About the Disease  
Overview
Symptoms
Anatomy & Physiology
Diagnosis
Staging
Types of Cancers
Treatment
Clinical Trials

Giving



Diagnosis of Gallbladder and Bile Duct Cancer: An Overview

Ultrasound CT Scan MRI ERCP CA19-9 FNA Biopsy



CA 19-9

This is a tumor marker for bile duct cancer that is measured through a blood test. It is useful in assisting with an initial diagnosis. However, it is more useful in measuring the effectiveness of cancer treatment by studying the patient's CA19-9 levels over time.

In general, before surgery, the higher the CA19-9 level is (normal CA 19-9 level is 40 units per milliliter), the larger the tumor is and the less chance that the tumor is resectable. For the purposes of evaluating treatment, a decreasing or stable CA19-9 level generally indicates an improved prognosis and an increasing level indicates the progression of disease.

Currently, there are not sufficiently accurate diagnostic blood tests for bile duct cancer. Very few cancers, such as prostate and liver cancers, can be confidently diagnosed solely on the basis of blood test results. Perfecting a suitable blood test for bile duct cancer is an area of active research because it would enable screening for individuals considered at-risk.


Accuracy:

CA19-9 is elevated in the blood of about 90% of individuals with bile duct cancer. Other blood tests such as CEA can be used in combination with CA 19-9 to improve the accuracy of the test. Supplemental imaging studies and tissue samples are required with CA19-9 levels for a definitive diagnosis.

CA19-9 can be used to track treatment progress of previously diagnosed bile duct cancer patients. This blood test in conjunction with periodic CT scans will show whether the cancer is in remission or is continuing to grow.


Results:

If your doctor suspects bile duct cancer, an abnormal CA 19-9 blood level will increase the suspicion. However, there are benign diseases of the bile ducts and pancreas that occasionally result in elevated CA 19-9 levels. For this reason CA 19-9 is not considered a diagnostic test.

  
   
Copyright © 2000-2014 The Johns Hopkins University Feedback | Disclaimer